iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption
December 29, 2020
International Multi-Center Study to Commence January 2021
University of Louisville’s Trial on IORT for Large Brain Lesion Treatments Accelerating
First European Patient Treated for Brain Metastasis with Xoft IORT System
NASHUA, N.H. – December 29, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the app... Continue reading
iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress
November 25, 2020
Growing Body of Evidence Supports Xoft Platform
Across Multiple Cancer Types
NASHUA, N.H. – November 25, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced that researchers from Miguel Servet University Hospital
in Zaragoza, Spain, will present new data from three clinical studies
supporting the efficacy of the expanded Xoft® Axxent® Electronic Brachytherapy (eBx... Continue reading
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers
October 23, 2020
iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors
NASHUA, N.H. – October 23, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase the expanded platform for the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at the American Society for Radiation Oncology... Continue reading
New Data Supports iCAD’s Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma
October 19, 2020
New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery
NASHUA, N.H. – October 19, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new, promising clinical results supporting the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the t... Continue reading
iCAD Responds to CMS’ Finalized Radiation Oncology Alternative Payment Model
September 20, 2020
IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced
NASHUA, N.H. – September 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, is providing additional comments following the Centers for Medicare & Medicaid Services’ (CMS) publication of a new Innovation Cen... Continue reading
iCAD Appoints Jeffrey Sirek as Senior Vice President and General Manager of Xoft
July 20, 2020
NASHUA, N.H. – July 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Jeffrey Sirek was appointed as Senior Vice President and General Manager of Xoft.
“We are very pleased to add Mr. Sirek to our Company. He brings to the team a proven track record of high sales productivity, brand development, marketing success, an... Continue reading
iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19
June 01, 2020
Leading breast cancer specialists to share best practices on leveraging the latest in cancer therapies to enhance patient care and minimize virus exposure
NASHUA, N.H. – June 1, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled “The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy,” on June 4, 2020 at 7 pm ET/4 pm... Continue reading
iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
May 13, 2020
Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives
Overall survival benefit reached statistical significance in the IORT group with tumors less than or equal to 2.5 cm3 (p<0.05)
NASHUA, N.H. – May 13, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solut... Continue reading
First Brain Tumor Treated with Xoft IORT in the United States
February 11, 2020
First U.S. procedure follows matched pair study indicating a promising improvement in overall survival
NASHUA, N.H. – February 11, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the first metastatic brain tumor was treated in the U.S. with intraoperative radiation therapy (IORT) using the Xoft® Axxe... Continue reading
iCAD Showcases Technology for Cancer “Discovery to Recovery” including ProFound AI Platform and Xoft System at Arab Health 2020 in Dubai
January 27, 2020
iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solution and a single-fraction therapy option for early-stage breast cancer
NASHUA, N.H. – January 27, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutio... Continue reading
iCAD Exhibiting New Updates and Enhanced Xoft Platform at ASTRO Including Single-Fraction IORT Solution for the Treatment of Early-Stage Breast Cancer
September 16, 2019
Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers
NASHUA, N.H. and CHICAGO – September 16, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase its latest advancements for the Xoft® Axxent® Electroni... Continue reading
iCAD Appoints R. Scott Areglado As Chief Financial Officer
May 06, 2019
NASHUA, N.H. -- May 6, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today appointed R. Scott Areglado as Chief Financial Officer. Mr. Areglado has been serving as interim Chief Financial Officer since December 2018, and previously held the role of Corporate Controller at iCAD since May 2011.
Continue reading
iCAD Wins Three-System Public Bid with Leading Cancer Organization in Spain, Expanding European Access to Innovative Cancer Treatments with the Xoft System
April 15, 2019
Two additional Spanish centers announce adoption of the Xoft System, totaling seven installations across four major regions in Spain
Internationally-recognized institutions strengthen portfolio of comprehensive cancer care solutions with iCAD’s state-of-the-art electronic brachytherapy technology
Continue reading
iCAD Appoints Stacey Stevens as President
March 28, 2019
Appointment establishes executive infrastructure to enhance strategic and operational momentum and capitalize on significant growth opportunities
Announcement follows pivotal FDA clearance and successful U.S. commercial launch of ProFound AI™ for digital breast tomosynthesis along... Continue reading
Long-Term Study of 1,000 Tumors Demonstrates Effectiveness of iCAD's Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment
January 07, 2019
Prospective trial shows
that intraoperative radiation therapy (IORT) is a clinically effective, faster
and easier alternative to whole breast radiation therapy following
breast-conserving surgery for selected low-risk patients at a median follow-up
of 36 months
NASHUA, N.H., (January 7, 2019) – iCAD, Inc.
(NASDAQ: ICAD), a global medical technology leader providing innovative
cancer detection and therapy solutions, today announced the results of a
long-term study conducted at Hoag Memorial Hospital Pre... Continue reading
iCAD Announces Retirement of CEO, Ken Ferry
November 09, 2018
Michael Klein, Chairman of the Board, to serve as Executive Chairman and Interim CEO
NASHUA, N.H., (November 9, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Ken Ferry has retired from his position as Chief Executive Officer (CEO) and stepped down as a Director of the Company, effective immediately. Michael Klein, Chairman of iCAD’s Bo... Continue reading
Navicent Health Adopts iCAD’s Breast Cancer Detection and Therapy Solutions to Enhance Patient Care
October 30, 2018
Prominent medical center is first in the United States to expand breast health offerings with iCAD’s PowerLook Tomo Detection solution and Xoft System
NASHUA, N.H., and Macon, GA, (October 30, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its complete suite of leading-edge breast health innovations including PowerLook® Tomo Detection,&... Continue reading
iCAD Announces New Clinical Data on the Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment Demonstrating Positive Results
October 23, 2018
Multi-center research presented at ASTRO 2018 shows IORT with the Xoft
System is safe with low recurrence and low morbidity in the treatment of breast
cancer
Company marks 20 years of innovations in targeted cancer care at the
conference
NASHUA, N.H. and SAN ANTONIO, Texas (Booth #3457)... Continue reading
Case Study: Why Several Leading Cancer Centers Chose the Xoft System for the Treatment of Early-Stage Breast Cancer
October 15, 2018
For more than 100 years, radiation has been
used to reduce the recurrence of cancer and improve survival. While this
treatment option presents important benefits, traditional radiation therapy has
significant side effects for patients.
Today, there are several innovative
technologies on the market that provide valuable health benefits as well as
time and cost savings for patients. One such technology is intraoperative
radiation therap... Continue reading
SUNY Upstate Medical University Selects iCAD’s Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment
October 09, 2018
Premier center becomes first in the region to offer intraoperative radiation
therapy with the leading-edge Xoft System to advance quality patient care in
New York State
NASHUA, N.H. and Syracuse, N.Y., (October 9, 2018) – iCAD,
Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today announced
that its Xoft® Axxent®
Electronic Brachytherapy (eBx®) System®... Continue reading
100 Comments